Free tool
FAERS Monitor: Humalog Kwikpen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020563 or its brand name (Humalog Kwikpen, Insulin Lispro Recombinant). Reports on generic versions are filed under their own applications.
Reports
129,052
Serious
60,658
47% of reports
Hospitalization
32,551
Death reported
5,766
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased36,329
- incorrect dose administered8,658
- blood glucose decreased8,320
- drug ineffective7,715
- visual impairment5,049
- nausea4,797
- malaise3,739
- fatigue3,696
- hypoglycaemia3,671
- fall3,343
- drug dose omission3,323
- diarrhoea3,188
- vomiting3,182
- pain3,051
- dyspnoea3,040
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,189 |
| 2005 | 1,265 |
| 2006 | 1,680 |
| 2007 | 1,554 |
| 2008 | 1,463 |
| 2009 | 1,792 |
| 2010 | 1,841 |
| 2011 | 2,034 |
| 2012 | 2,107 |
| 2013 | 1,732 |
| 2014 | 4,580 |
| 2015 | 24,791 |
| 2016 | 8,487 |
| 2017 | 9,234 |
| 2018 | 8,994 |
| 2019 | 8,984 |
| 2020 | 9,182 |
| 2021 | 7,793 |
| 2022 | 6,793 |
| 2023 | 5,902 |
| 2024 | 5,555 |
| 2025 | 8,089 |
| 2026 | 4,011 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,925,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose increasedSignal | 36,329 | 38.7 | 38.3 | 1,086,464 |
| blood glucose decreasedSignal | 8,320 | 33.9 | 33.2 | 220,417 |
| hypoglycaemiaSignal | 3,671 | 13.3 | 12.8 | 38,552 |
| visual impairmentSignal | 5,049 | 6.9 | 6.7 | 24,478 |
| incorrect dose administeredSignal | 8,658 | 6.4 | 6.3 | 38,248 |
| drug dose omissionSignal | 3,323 | 3.3 | 3.2 | 5,327 |
| fall | 3,343 | 1.6 | 1.6 | 847 |
| malaise | 3,739 | 1.4 | 1.3 | 419 |
| vomiting | 3,182 | 1.1 | 1.1 | 31 |
| nausea | 4,797 | 1.0 | 1.0 | 1 |
| drug ineffective | 7,715 | 1.0 | 0.9 | 18 |
| dyspnoea | 3,040 | 0.9 | 0.8 | 56 |
| pain | 3,051 | 0.8 | 0.8 | 142 |
| diarrhoea | 3,188 | 0.8 | 0.8 | 156 |
| fatigue | 3,696 | 0.8 | 0.7 | 255 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.